The current study has addressed the role of PTEN loss in intrinsic resistance to the BRAF inhibitor PLX4720. Immunohistochemical staining of a tissue array covering all stages of melanocytic neoplasia (n=192) revealed PTEN expression to be lost in >10% of all melanoma cases. Although PTEN expression status did not predict for sensitivity to the growth inhibitory effects of PLX4720, it was predictive for apoptosis, with only limited cell death observed in melanomas lacking PTEN expression (PTEN-). Mechanistically, PLX4720 was found to stimulate AKT signaling in the PTEN-but not the PTEN+ cell lines. Liquid chromatography multiple reaction monitoring mass spectrometry (LC-MRM) was performed to identify differences in apoptosis signaling between the two cell line groups. PLX4720 treatment significantly increased BIM expression in the PTEN+ (>14-fold) compared to the PTEN-cell lines (4-fold). A role for PTEN in the regulation of PLX4720-mediated BIM expression was confirmed by siRNA knockdown of PTEN and through re-introduction of PTEN into cells that were PTEN-. Further studies showed that siRNA knockdown of BIM significantly blunted the apoptotic response in PTEN+ melanoma cells. Dual treatment of PTEN-cells with PLX4720 and a PI3K inhibitor enhanced BIM expression at both the mRNA and protein level and increased the level of apoptosis through a mechanism involving AKT3 and the activation of FOXO3a. In conclusion, we have shown for the first time that loss of PTEN contributes to intrinsic BRAF inhibitor resistance via the suppression of BIM-mediated apoptosis.
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Introduction
One defining moment in our understanding of melanoma initiation and progression was the discovery of activating V600E mutations in BRAF in >50% of melanomas (1, 2) . There is now good evidence that mutated BRAF is a bona fide therapeutic target in melanoma (3) (4) (5) . A number of BRAF specific small molecule kinase inhibitors have been developed that are now undergoing intense preclinical and clinical investigation (6, 7) . In pre-clinical studies, the BRAF inhibitors PLX4720 and PLX4032 potently inhibited BRAF kinase activity in melanoma cells harboring the BRAF V600E mutation and were cytostatic and cytotoxic in both in vitro cell culture systems and in vivo xenograft melanoma models (5, 6, 8) . This promising pre-clinical activity was mirrored by a recent phase I clinical trial of PLX4032 in advanced melanoma in which >80% of patients showed some level of tumor regression (4) . Although most patients with BRAF V600E mutated melanoma showed some response to PLX4032, ~20% of those treated did not meet the RECIST criteria threshold for a response (4, 9) . Although the mechanisms of intrinsic BRAF inhibitor resistance are not well understood, increased cyclin D1 expression (in ~17% of BRAF mutated melanomas) allows for cell cycle entry when MAPK signaling is abrogated (10, 11) . It is also likely that constitutive activity in other pathways, such as phospho-inositide 3-kinase (PI3K)/AKT, may contribute to intrinsic resistance by limiting the apoptotic response (12, 13) . One of the most critical negative regulators of AKT activity is the phosphatase and tensin homologue (PTEN), which hydrolyses PI-3,4,5-P 3 to PI-4,5-P 2 , ultimately preventing the phosphorylation of AKT (14) . In the present study we identify loss of PTEN expression, observed in >10% of melanoma specimens, as being responsible for increased PI3K/AKT signaling when BRAF is inhibited. We further show that PTEN loss contributes to the intrinsic resistance of BRAF V600E-mutated melanoma cell lines to PLX4720 by suppressing the expression of the pro-apoptotic protein BIM.
Cell culture and MTT assay
Melanoma cell lines were a gift from Dr. Meenhard Herlyn (The Wistar Institute, Philadelphia, PA) and were grown as described in (8) . MTT assays were performed as described in (15) . The identity of the Wistar Institute cell lines was confirmed using the Coriell Institute (Camden, NJ) cell identity mapping kit. The M233 cell line was derived as described in (16) and its identity confirmed by Biosynthesis Inc (Lewisville, Tx) by STR validation analysis.
Generation WM793TR-PTEN cell lines
Wild-type and G129E PTEN (phosphatase deficient) human cDNAs were a gift from Dr. Bill Sellers (Dana-Farber Cancer Institute) (17) . WM793TR-PTEN-wt, WM793TR-PTEN-G129E and WM793 cells overexpressing wild-type BAD were a kind gift from Dr Andrew Aplin (Kimmel Cancer Center, Philadelphia, PA).
Inducible expression of PTEN was obtained by treatment of cultures with doxycycline at a final concentration of 100ng/ml. The WM793 cells stably expressing wild-type BAD were generated as described in (18) . Total RNA was isolated using Qiagen's RNeasy mini kit. The following TaqMan® Gene Expression Assays primer/probes were used: Hs00197982_m1 (BIM), P/N 4319413E (18S) and Hs99999905_m1 (GAPDH). The 18S + GAPDH data were used for normalizing BIM. After a 2-min incubation at 50°C, AmpliTaq Gold was activated by a 10-min incubation at 95°C, followed by 40 PCR cycles consisting of 15 s of denaturation at 95°C and hybridization of probe and primers for 1 min at 60°C. All standards and samples were tested in triplicate wells and data were analyzed using SDS software version 2.3.
Immunofluorescence staining
Cells were plated onto coverslips and treated with PLX4720 for 48hrs before being fixed and permeabilized as previously described (15) and imaged with a Leica confocal microscope at 40X magnification.
3D spheroid assays
Collagen implanted spheroids were prepared using the liquid overlay method (12) and were treated with 3µM of PLX4720, 10µM LY294002 or both drugs in combination for 72hr before being analyzed by fluorescence microscopy as described in (11) . In other studies, spheroids were treated for 72hrs, washed 3X in fresh media and allowed to recover for 120hrs before analysis.
Immunohistochemical staining
A melanoma tissue array was generated from de-identified formalin-fixed 
Liquid chromatography, multiple reaction monitoring mass spectrometry (LC-MRM) analysis
Whole cell proteins extracts were separated by SDS-PAGE, visualized with Coomassie Brilliant Blue G-250 (Bio-Rad, Hercules, CA) and selected bands were excised. Following digestion, the internal standard peptides were added in 2% acetonitrile. LC-MRM analysis was performed as described in (20) with three replicate analyses for each peptide. Quantification was achieved by using the sum of the peak areas for all detected transitions using Xcalibur QuanBrowser (Thermo, San Jose, CA). Relative protein expression is determined using the ratio of peak area of the native peptide to corresponding internal standard (Supplemental Table 2 ).
Statistical analysis
Data show the mean of at least three independent experiments ± the S.E. mean, unless stated otherwise. GraphPad Prism 5 statistical software was used to perform the Student's T-test where *indicates P≤ 0.05. 
Results

The role of PTEN loss in the response to PLX4720
Initial studies identified 6 BRAF mutated melanoma cell lines that retained PTEN expression (PTEN+; WM35, WM51, WM164, WM983A, 451Lu, SK-Mel-28) and 6 that lacked PTEN expression (PTEN-; WM239A, WM266-4, WM793, 1205Lu, WM9, M233) ( Figure 1A ; Supplemental Table 1 ). Genomic analysis showed the WM9 and M233 cell lines to be homozygously deleted for PTEN and the WM793 and 1205lu cell lines be hemizygously deleted for PTEN in conjunction with a PTEN mutation (Supplemental Table 1 ). The PTEN+ cell lines had lower constitutive levels of pAKT (Ser473) compared to the PTEN-( Figure 1A ). Similar levels of pAKT (Thr308) 
knockdown of BIM led to an impairment of PLX4720 (3 and 10µM) induced apoptosis ( Figure 5D ).
Dual BRAF/PI3K inhibition enhances BIM expression and apoptosis in PTEN-cells
One of the major effects of PTEN is to limit PIP3 levels through its lipid phosphatase activity. We next treated PTEN-cell lines with a PI3K inhibitor (GDC-0941, 3µM or LY294002 10µM), PLX4720 (3 and 10µM), or the two drugs in combination, and showed that combined PI3K and BRAF inhibition increased the level of BIM expression in both Western blot and immunofluorescence studies ( Figure 6A ). Both the MAPK and PI3K/AKT pathways are known to regulate BIM RNA expression levels through the transcription factor FOXO3a We began by investigating PTEN expression across a large sample of melanocytic lesions and found that PTEN was lost in 10-27% of melanomas.
Although PTEN loss overlapped with the level of pAKT staining it was not always well correlated, agreeing with previous observations that other mechanisms may underlie the increased AKT activation associated with melanoma progression (35) . Our results agree with other published studies on smaller numbers of melanoma samples (n=16-39), and confirm that reduced PTEN expression is a significant oncogenic event for a restricted subgroup of melanomas (31, 32, 36) .
Although PTEN was retained in non-atypical nevi, a significant number (23%) of atypical nevi lacked expression, suggesting this to be an early event in melanoma development. This idea is supported by recent mouse modeling studies showing that the conditional expression of the BRAF V600E mutation leads to melanoma development only when PTEN is suppressed (28) .
Although lack of PTEN expression did not predict for sensitivity of BRAF V600E mutated melanoma cell lines to the growth inhibitory effects of PLX4720, there were significant differences in PLX4720-mediated apoptosis between PTEN+ and PTEN-melanoma cell lines. Initially, we hypothesized that PTEN-melanoma cell lines would show higher levels of AKT activity and that this would mediate resistance to PLX4720. Instead, we observed that drug treatment increased AKT AKT plays a critical role in cancer development through its ability to regulate cell survival through the direct phosphorylation of BAD, the stimulation of ribosomal S6 kinase signaling, the inhibition of FOXO signaling and the inhibition of glycogen synthase 3-kinase (35) . To determine the mechanism of PLX4720-induced apoptosis induction in the PTEN+ melanoma cell lines, LC-MRM analysis was used to quantify the relative expression of members of the Bcl-2 protein family (20) . For the majority of proteins examined, PLX4720 treatment was associated with very similar dynamics in both the PTEN+ and PTEN-cell lines. These findings agree with previous studies and show that BRAF inhibition leads to an increase in the expression in the pro-apoptotic protein BIM (18, 39, 40) . In contrast to these studies, which did not distinguish between PTEN+ and PTEN-cell lines, the LC-MRM analysis allowed us to identify significant PTENdependent differences in the level of PLX4720-induced BIM expression. BIM is a pro-apoptotic BH3-only member of the Bcl-2 protein family that exists in three major splice forms; extra long (BIM-EL), long (BIM-L) and short (BIM-S) (41, 42) . CAN-10-2954 pathways, including BRAF/MEK/ERK, JNK, p38 MAPK and PI3K/AKT (39, 41, 43, 44) . In melanoma, the BRAF V600E mutation regulates BIM expression through the MEK/ERK pathway-mediated phosphorylation of the extra-long form of BIM (BIM-EL) at Serine 69, leading to its subsequent degradation by the proteasome (39, 45) . Our study is the first to demonstrate that the level of BIM expression following BRAF inhibition is also determined by PTEN status and that the differing levels of BIM induction can determine the extent of apoptosis induction when BRAF is inhibited. Apoptosis control in melanoma cells is complex and increased AKT signaling is likely to regulate survival at multiple levels. One of the best known pro-survival substrates of AKT is the cell death inducing molecule BAD. AKT inactivates BAD via phosphorylation at Ser99, which prevents it's binding to Bax and relieves the antagonism of Bax on Bcl-2 and Bcl-XL (18) . A role for Bad inactivation in the escape of PTEN-cells from PLX4720-induced apoptosis was suggested by the preferential inactivation of BAD when BRAF was inhibited and the fact that overexpression of BAD sensitized the same cell line to PLX4720-induced apoptosis. Another candidate pro-apoptotic factor upregulated in melanoma cells following BRAF/MEK/ERK inhibition is BMF (Bcl-2 modifying factor) (40, 46) . BMF, which is also regulated through the PI3K/AKT pathway, mediates its apoptotic effects through binding to Mcl-1. Although it is possible that BMF may also be differentially regulated in PTEN+/-cells, we, like other groups, were unable to confirm the selectivity of commercially available BMF antibodies (40, 47 
In addition to regulating PIP3 levels in the cytoplasm through its lipid phosphatase function, PTEN also localizes to the nucleus where it exerts its tumor suppressor function through lipid phosphatase-independent effects upon the regulation of chromosomal integrity, p53 acetylation and the expression of cyclin D1 (48) 
